Management of CKD Caused by
Glomerular Diseases
This comprehensive course provides a deep dive into the pathophysiology, diagnosis, and management of glomerular diseases, with a specialized focus on IgA Nephropathy (IgAN).
Participants will explore the evolution from traditional immunosuppression to novel, targeted therapies, all while centering on the lived experiences of the patient.
By the end of this course, learners will be able to:
-
Identify and evaluate glomerulonephritis (GN) through appropriate interpretation of screening markers (eGFR, UACR), understanding of underlying pathophysiology, and timely referral for specialist evaluation.
-
Compare traditional and emerging therapies for GN, particularly IgA nephropathy, including mechanisms of action, clinical evidence, safety profiles, and evolving roles in therapy.
-
Apply current guideline-based and evidence-informed strategies to patient cases, individualizing treatment decisions to optimize clinical outcomes while considering patient burden and risk–benefit profiles.
Overall courses will include:
-
Glomerulonephritis: A primer on the detection, diagnosis, and an appreciation for the patient experience
-
Primer on Immunosuppressants used in Glomerular Disease
-
Part 1– Basics and Traditional Immunosuppressants
-
Part 2– Indications and Novel Agents
-
-
Targeting IgA Nephropathy: Insights into Pathogenesis, Novel Therapies, and Clinical Application
-
FSGS (Coming Soon)
Course Modules
The focus of this module is to understand the critical role of GN in Chronic Kidney Disease (CKD). This module covers screening essentials (eGFRm UACR, hematuria) and the unique burden these diseases place on the patient. Key Takeaway: Recognize when clinical markers indicate GN and necessitate a specialist referral. Objectives Review the historical context for distrust of Black persons in the US health system Discuss current health and medication-related disparities that Black persons with chronic kidney disease are experiencing Characterize different types of bias that affect equitable health care Identify resources for health care professionals to educate themselves and others on how to address various biases to improve health equity and pharmacoequity in Black persons.
The focus of this module is to take a foundational look at traditional regimens (e.g. Ponticelli, steroids, cyclophosphamide). Key Takeaway: Explain the risk/benefit ratio of non-targeted therapies and identify appropriate supportive therapies.
Learning Objectives: - Describe the indications for use of immunosuppressant therapy in glomerulonephritis. - Identify and describe novel agents used to reduce toxicities of traditional agents
Learning Objectives: - Explain the 4 hit hypothesis of the pathogenesis of IgA nephropathy - Compare and contrast mechanism of action, side effects, and role in therapy for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, atrasentan, and iptacopan) - Describe evidence for new treatments for IgA nephropathy (budesonide delayed release capsules, sparsentan, atrasentan, and iptacopan) - Apply updated guideline to a patient case in choosing the appropriate treatment from either traditional or new targeted treatments, or a combination of traditional and new treatments
Stay tuned for upcoming modules in this series covering:
-
FSGS (Coming Soon)